BACKGROUND	Gemcitabine and paclitaxel ( Taxol ) each provides an efficacious non-platinum option for the treatment of advanced non-small-cell lung cancer ( NSCLC ) , but the optimal dosage and schedule of the two agents used in combination are not well defined .\